Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Panbela Therapeutics, Inc. (PBLA)

1.31   0.03 (2.34%) 09-29 15:59
Open: 1.28 Pre. Close: 1.28
High: 1.35 Low: 1.22
Volume: 14,615 Market Cap: 4(M)

Technical analysis

as of: 2023-09-29 4:29:35 PM
Short-term rate:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Mid-term rate:       
Target: Six months: 1.65     One year: 1.79
Support: Support1: 1.21    Support2: 1
Resistance: Resistance1: 1.41    Resistance2: 1.53
Pivot: 1.31
Moving Average: MA(5): 1.28     MA(20): 1.34
MA(100): 3.76     MA(250): 57.89
MACD: MACD(12,26): -0.1     Signal(9): -0.2
Stochastic oscillator: %K(14,3): 36.1     %D(3): 30.2
RSI: RSI(14): 38.7
52-week: High: 384  Low: 1.21
Average Vol(K): 3-Month: 928 (K)  10-Days: 22 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ PBLA ] has closed above bottom band by 47.2%. Bollinger Bands are 94.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for {EMPTY} bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.35 - 1.36 1.36 - 1.36
Low: 1.21 - 1.21 1.21 - 1.22
Close: 1.3 - 1.31 1.31 - 1.32

Company Description

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.

Headline News

Tue, 26 Sep 2023
Panbela Announces Issuance of New Patent in China for Claims of ... - BioSpace

Tue, 19 Sep 2023
Panbela to Present at the LD Micro Investor Conference - GlobeNewswire

Tue, 05 Sep 2023
Panbela Announces Issuance of New Patent in Chile for Claims of a ... - GlobeNewswire

Mon, 28 Aug 2023
Panbela to Present at H.C. Wainwright 25th Annual Global - GlobeNewswire

Sun, 13 Aug 2023
Panbela Therapeutics, Inc. (NASDAQ:PBLA) Q2 2023 Earnings Call Transcript - Yahoo Finance

Wed, 19 Jul 2023
Panbela Therapeutics to Receive a Total Up to $9.5 Million for ... - GlobeNewswire

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 3 (M)
Shares Float 3 (M)
% Held by Insiders 0.8 (%)
% Held by Institutions 4.4 (%)
Shares Short 84 (K)
Shares Short P.Month 49 (K)

Stock Financials

EPS 179.61
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.84
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -93.6
Return on Equity (ttm) 0
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0
Operating Cash Flow -22 (M)
Levered Free Cash Flow -9 (M)

Stock Valuations

PE Ratio 0
PEG Ratio 0
Price to Book value 0.71
Price to Sales 0
Price to Cash Flow -0.18

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.